GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zimmer Biomet Holdings Inc (NYSE:ZBH) » Definitions » EBITDA

Zimmer Biomet Holdings (Zimmer Biomet Holdings) EBITDA

: $2,220 Mil (TTM As of Dec. 2023)
View and export this data going back to 2001. Start your Free Trial

Zimmer Biomet Holdings's EBITDA for the three months ended in Dec. 2023 was $576 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $2,220 Mil.

During the past 12 months, the average EBITDA Growth Rate of Zimmer Biomet Holdings was 48.50% per year. During the past 3 years, the average EBITDA Growth Rate was 30.20% per year. During the past 5 years, the average EBITDA Growth Rate was 9.30% per year. During the past 10 years, the average EBITDA Growth Rate was 2.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Zimmer Biomet Holdings was 55.70% per year. The lowest was -18.40% per year. And the median was 4.50% per year.

Zimmer Biomet Holdings's EBITDA per Share for the three months ended in Dec. 2023 was $2.76. Its EBITDA per share for the trailing twelve months (TTM) ended in Dec. 2023 was $10.59.

During the past 12 months, the average EBITDA per Share Growth Rate of Zimmer Biomet Holdings was 49.00% per year. During the past 3 years, the average EBITDA per Share Growth Rate was 29.70% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 8.70% per year. During the past 10 years, the average EBITDA per Share Growth Rate was 0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Zimmer Biomet Holdings was 43.60% per year. The lowest was -18.90% per year. And the median was 5.90% per year.


Zimmer Biomet Holdings EBITDA Historical Data

The historical data trend for Zimmer Biomet Holdings's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zimmer Biomet Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,138.80 1,005.30 1,645.10 1,494.70 2,220.20

Zimmer Biomet Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 196.30 566.80 565.90 511.50 576.00

Competitive Comparison

For the Medical Devices subindustry, Zimmer Biomet Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zimmer Biomet Holdings EV-to-EBITDA Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Zimmer Biomet Holdings's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Zimmer Biomet Holdings's EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Zimmer Biomet Holdings's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2023, Zimmer Biomet Holdings's EBITDA was $2,220 Mil.

Zimmer Biomet Holdings's EBITDA for the quarter that ended in Dec. 2023 is calculated as

Zimmer Biomet Holdings's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Dec. 2023, Zimmer Biomet Holdings's EBITDA was $576 Mil.

EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,220 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Zimmer Biomet Holdings  (NYSE:ZBH) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Zimmer Biomet Holdings EBITDA Related Terms

Thank you for viewing the detailed overview of Zimmer Biomet Holdings's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Zimmer Biomet Holdings (Zimmer Biomet Holdings) Business Description

Traded in Other Exchanges
Address
345 East Main Street, Warsaw, IN, USA, 46580
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Executives
Syed A. Jafry director 345 E. MAIN STREET, WARSAW IN 46580
Sreelakshmi Kolli director C/O ALIGN TECHNOLOGY INC., 2820 ORCHARD PARKWAY, SAN JOSE CA 94131
Christopher B Begley director
Robert Hagemann director 3 GIRALDA FARMS, MADISON NJ 07940
Michael W Michelson director 2800 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Betsy J Bernard director 711 HIGH STREET, DES MOINES IA 50392-0300
Arthur J Higgins director C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Chad F Phipps officer: Assoc. Gen. Counsel, Corp. Sec C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Zuilen Wilfred Van officer: Pres, Europe, M. East & Africa 345 E. MAIN STREET, WARSAW IN 46580
Paul A Stellato officer: VP, Controller & CAO C/O XYLEM INC, 1 INTERNATIONAL DRIVE, RYE BROOK NY 10573
Sang Yi officer: President, Asia Pacific 345 E. MAIN STREET, WARSAW IN 46580
Lori Winkler officer: SVP and CHRO 345 E. MAIN STREET, WARSAW IN 46580
Rachel Ellingson officer: SVP & CSO 345 E MAIN STREET, WARSAW K7 46580
Bryan C Hanson director, officer: President and CEO ZIMMER BIOMET HOLDINGS, 345 E. MAIN STREET, WARSAW IN 46580
Aure Bruneau officer: Group President 345 E. MAIN STREET, WARSAW IN 46580